News Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Continue Reading Previous FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%Next Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021 Related Stories News DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate Healing in Infected, Chronic Wounds News Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update News LIDDS and Pharmidea signs manufacturing agreement News LIDDS Interim report January – December 2020 News Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine News argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
